http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 06:33:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+12/26638018.html si-local-file:///var/storage/secattach/20260612/26638018.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+12/26638018.html Fri, 12 Jun 2026 06:33:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+12/26638018.html si-local-file:///var/storage/secattach/20260612/26638018.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+12/26638018.html Fri, 12 Jun 2026 06:33:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+12/26638018.html si-local-file:///var/storage/secattach/20260612/26638018.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+12/26638018.html Fri, 12 Jun 2026 06:33:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+11/26634030.html si-local-file:///var/storage/secattach/20260611/26634030.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+11/26634030.html Thu, 11 Jun 2026 10:42:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+11/26634030.html si-local-file:///var/storage/secattach/20260611/26634030.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+11/26634030.html Thu, 11 Jun 2026 10:42:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+11/26634030.html si-local-file:///var/storage/secattach/20260611/26634030.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+11/26634030.html Thu, 11 Jun 2026 10:42:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+10/26628303.html si-local-file:///var/storage/secattach/20260610/26628303.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+10/26628303.html Wed, 10 Jun 2026 10:37:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+10/26628303.html si-local-file:///var/storage/secattach/20260610/26628303.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+10/26628303.html Wed, 10 Jun 2026 10:37:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+10/26628303.html si-local-file:///var/storage/secattach/20260610/26628303.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+10/26628303.html Wed, 10 Jun 2026 10:37:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26622921.html si-local-file:///var/storage/secattach/20260609/26622921.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26622921.html Tue, 09 Jun 2026 13:37:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26622921.html si-local-file:///var/storage/secattach/20260609/26622921.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26622921.html Tue, 09 Jun 2026 13:37:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26622921.html si-local-file:///var/storage/secattach/20260609/26622921.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26622921.html Tue, 09 Jun 2026 13:37:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/Press+Releases/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html <p>DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=XayG3E74G-kX2BQ0P2T-Sw1VCdiMiVcvUadWXSg2wi--MBPQY9M80Mp2Fpy_bCNadkdnxYOtvS_Aef_F0xa18IegbHaGsA9We_rndgb26sw=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade.</p> <p>One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions http://www.streetinsider.com/Press+Releases/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html Tue, 09 Jun 2026 09:44:01 -0400 GSK NUVL PFE http://www.streetinsider.com/Press+Releases/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html <p>DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=XayG3E74G-kX2BQ0P2T-Sw1VCdiMiVcvUadWXSg2wi--MBPQY9M80Mp2Fpy_bCNadkdnxYOtvS_Aef_F0xa18IegbHaGsA9We_rndgb26sw=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade.</p> <p>One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions http://www.streetinsider.com/Press+Releases/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html Tue, 09 Jun 2026 09:44:01 -0400 GSK NUVL PFE http://www.streetinsider.com/Press+Releases/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html <p>DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=XayG3E74G-kX2BQ0P2T-Sw1VCdiMiVcvUadWXSg2wi--MBPQY9M80Mp2Fpy_bCNadkdnxYOtvS_Aef_F0xa18IegbHaGsA9We_rndgb26sw=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade.</p> <p>One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions http://www.streetinsider.com/Press+Releases/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html Tue, 09 Jun 2026 09:44:01 -0400 GSK NUVL PFE http://www.streetinsider.com/Globe+Newswire/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html <p>DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=XayG3E74G-kX2BQ0P2T-Sw1VCdiMiVcvUadWXSg2wi--MBPQY9M80Mp2Fpy_bCNadkdnxYOtvS_Aef_F0xa18IegbHaGsA9We_rndgb26sw=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade.</p> <p>One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions http://www.streetinsider.com/Globe+Newswire/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html Tue, 09 Jun 2026 09:44:01 -0400 GSK NUVL PFE http://www.streetinsider.com/Globe+Newswire/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html <p>DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=XayG3E74G-kX2BQ0P2T-Sw1VCdiMiVcvUadWXSg2wi--MBPQY9M80Mp2Fpy_bCNadkdnxYOtvS_Aef_F0xa18IegbHaGsA9We_rndgb26sw=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade.</p> <p>One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions http://www.streetinsider.com/Globe+Newswire/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html Tue, 09 Jun 2026 09:44:01 -0400 GSK NUVL PFE http://www.streetinsider.com/Globe+Newswire/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html <p>DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=XayG3E74G-kX2BQ0P2T-Sw1VCdiMiVcvUadWXSg2wi--MBPQY9M80Mp2Fpy_bCNadkdnxYOtvS_Aef_F0xa18IegbHaGsA9We_rndgb26sw=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade.</p> <p>One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions http://www.streetinsider.com/Globe+Newswire/Cancer%27s+Toughest+Targets+Are+Drawing+Wall+Street%27s+Attention+as+Oncology+Innovation+Accelerates/26621749.html Tue, 09 Jun 2026 09:44:01 -0400 GSK NUVL PFE http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26619860.html si-local-file:///var/storage/secattach/20260609/26619860.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26619860.html Tue, 09 Jun 2026 06:19:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26619860.html si-local-file:///var/storage/secattach/20260609/26619860.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Jun+09/26619860.html Tue, 09 Jun 2026 06:19:00 -0400 GSK GSK O.00496275